Quick Answer
Aligos Therapeutics, Inc. reported Operating Income of -$87.98 million for fiscal year 2025.
Aligos Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$87.98M | +1.3% |
| 2024 | -$89.15M | -1.2% |
| 2023 | -$88.13M | +9.7% |
| 2022 | -$97.58M | +24.0% |
| 2021 | -$128.32M | -31.2% |
| 2020 | -$97.83M | -81.0% |
| 2019 | -$54.04M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$28.36M | -40.9% | -52.7% |
| June 30, 2025 | -$18.57M | +29.7% | +3.5% |
| March 31, 2025 | -$19.24M | +12.7% | +4.4% |
| September 30, 2024 | -$20.13M | -5.6% | +23.8% |
| June 30, 2024 | -$26.41M | -38.0% | -19.8% |
| March 31, 2024 | -$22.05M | +7.8% | -15.6% |
| September 30, 2023 | -$19.07M | -0.6% | +0.4% |
| June 30, 2023 | -$19.14M | +6.1% | +20.0% |
- Aligos Therapeutics, Inc. showed an increase of +1.3% in Operating Income compared to the prior fiscal year.
- Over the 2019–2025 period, Aligos Therapeutics, Inc.’s operating income has declined by 62.8% (from -$54.04 million to -$87.98 million).
- The most recent figure is from Aligos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: